Fabry Disease Treatment Market Size Forecast: Revenue and CAGR by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Fabry Disease Treatment Industry In 2025?

The Fabry disease treatment market size has demonstrated robust growth in recent years. It is projected to expand from $2.09 billion in 2024 to $2.27 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.8%. This historical expansion can be attributed to several contributing factors, including an increase in awareness and diagnosis rates, the rising adoption of enzyme replacement therapies, the growing use of chaperone therapies, advancements in healthcare infrastructure, a surge in investment dedicated to rare disease research, an expanding population, and heightened regulatory incentives for orphan drugs.

The fabry disease treatment market is projected to experience robust expansion over the coming years. It is forecast to reach $3.13 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.3%. This anticipated growth during the forecast period is driven by factors such as the increasing prevalence of the disease, rising awareness and diagnosis rates, an expanding healthcare infrastructure, growing investment in rare disease research, greater patient awareness, and broadening reimbursement policies. Key trends expected in this period involve advancements in gene therapy, progress in enzyme replacement therapies, improved diagnostic techniques, the development of novel therapies, and the integration of digital health technologies for patient management.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16421&type=smp

What Are The Main Drivers Boosting The Fabry Disease Treatment Industry’s Expansion?

The increasing prevalence of renal diseases is set to drive the growth of the fabry disease treatment market moving forward. These conditions, also known as kidney diseases, encompass any ailments that hinder kidney function. The number of renal disease cases is on the rise due to genetic predispositions, lifestyle choices, environmental factors, and pre-existing health issues. Fabry disease stems from the accumulation of globotriaosylceramide (Gb3) in kidney cells, leading to damage and dysfunction, which highlights the critical need for early detection and intervention to prevent kidney complications. For example, in December 2023, the Australian Bureau of Statistics, an Australian government agency, reported that 246,200 people (1.0% of the population) had kidney disease in 2022, marking a 0.2% increase over the past decade. Thus, the rising occurrence of renal diseases is fueling the expansion of the fabry disease treatment market.

What Are The Key Segments In The Fabry Disease Treatment Market?

The fabry disease treatmentmarket covered in this report is segmented –

1) By Treatment: Substrate Reduction Therapy; Enzyme Replacement Therapy; Chaperone Treatment; Other Treatments

2) By Route Of Administration: Oral Route; Intravenous Route

3) By Disease Severity: Classic Fabry Disease; Late-Onset Fabry Disease

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Substrate Reduction Therapy: Migalastat Hydrochloride (Galafold); Other Substrate Reduction Therapies

2) By Enzyme Replacement Therapy: Agalsidase Beta (Fabrazyme); Agalsidase Alfa (Replagal); Other Enzyme Replacement Therapies

3) By Chaperone Treatment: Migalastat Hydrochloride (Galafold)

4) By Other Treatments: Gene Therapy; Symptomatic Treatment

What Trends Are Expected To Drive The Fabry Disease Treatment Market?

Major companies involved in the Fabry disease treatment market are developing plant cell-based treatments, aiming to improve therapeutic effectiveness, reduce expenses, and enhance patient outcomes through innovative and sustainable strategies. Plant cell-based treatment for Fabry disease involves leveraging plant cells to produce enzymes that are lacking in individuals afflicted with the condition. These enzymes, derived from plants, can serve as a therapeutic option to substitute the missing or dysfunctional enzymes within the body, thereby aiming to alleviate symptoms and improve the health of patients affected by Fabry disease. For example, in May 2023, Chiesi Global Rare Diseases, an Italy-based pharmaceutical company, and Protalix BioTherapeutics Inc., an Israel-based pharmaceutical company, secured approval for ELFABRIO. ELFABRIO offers an alternative treatment choice for individuals suffering from Fabry disease. It is an enzyme replacement therapy (ERT) where the recombinant human a-Galactosidase-A enzyme is generated in plant-cell culture and subsequently modified with PEGylation to significantly extend its half-life. This treatment reduces the required frequency of administration, increases convenience, and improves the overall management of Fabry disease symptoms, thus enhancing patients’ quality of life.

Which Leading Players Are Enhancing Their Fabry Disease Treatment Market Presence Worldwide?

Major companies operating in the fabry disease treatment market are Sanofi S.A., GSK plc, Takeda Pharmaceutical Company Limited, CHIESI Farmaceutici S.p.A., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Sangamo Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Centogene N.V., Protalix BioTherapeutics, Avrobio Inc., ISU Abxis, Synageva BioPharma Corp., Greenovation Biotech GmbH, CANbridge Pharmaceuticals, Freeline, 4D Molecular Therapeutics, Abeona Therapeutics Inc., GC Biopharma Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Fabry Disease Treatment Market?

North America was the largest region in the fabry disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Fabry Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16421&type=smp

Browse Through More Reports Similar to the Global Fabry Disease Treatment Market 2025, By The Business Research Company

Sewage Treatment Facilities Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sewage-treatment-facilities-global-market-report

Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-bph-treatment-devices-and-equipment-global-market-report

Wastewater Treatment Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wastewater-treatment-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795